BA 1201
Alternative Names: Anti-PDL1/TGF-bifunctional fusion protein - Shandong Boan Biotechnology; BA-1201; TS-1905Latest Information Update: 19 Feb 2024
At a glance
- Originator Shandong Boan Biotechnology
- Developer Luye Pharma Group; Shandong Boan Biotechnology
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cervical cancer
- Discontinued Cancer; Cholangiocarcinoma; Gastric cancer; Gastrointestinal cancer; Non-small cell lung cancer; Small cell lung cancer; Urogenital cancer
Most Recent Events
- 19 Feb 2024 Discontinued - Phase-I for Gastrointestinal cancer (Late-stage disease) in China (Parenteral) (Shandong Boan Biotechnology pipeline February 2024)
- 19 Feb 2024 Discontinued - Phase-I for Non-small cell lung cancer in China (Parenteral) (Shandong Boan Biotechnology pipeline February 2024)
- 19 Feb 2024 Discontinued - Phase-I for Small cell lung cancer in China (Parenteral) (Shandong Boan Biotechnology pipeline February 2024)